News brief­ing: Ab­b­Vie part­ner Teneo­bio ex­pands tech li­cense with CAR-T play­er Po­sei­da; Ar­genx buys PRV from Bay­er for $98M

Teneo­bio may be best known for its pact with Ab­b­Vie and Gilead, but be­fore its big break the bis­pe­cif­ic play­er had li­censed its an­ti­bod­ies for a dif­fer­ent use: as binders in CAR-T ther­a­pies be­ing de­vel­oped by Po­sei­da.

Now, the biotechs are ex­pand­ing their part­ner­ship, with Po­sei­da ex­er­cis­ing four op­tions to de­ploy Teneo­bio’s heavy chain on­ly do­main an­ti­bod­ies com­mer­cial­ly.

The com­mer­cial li­cens­ing fees re­mained un­der wraps, but Teneo­bio is el­i­gi­ble for $250 mil­lion in mile­stones for these CAR-Ts against undis­closed tar­gets.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.